Enteric Nervous System
Introduction
flowchart TD
enteric_nervous_system_expande["enteric-nervous-system-expanded"]
enteric_nervous_system_expande["Introduction"]
enteric_nervous_system_expande -->|"related to"| enteric_nervous_system_expande
style enteric_nervous_system_expande fill:#81c784,stroke:#333,color:#000
enteric_nervous_system_expande["often"]
enteric_nervous_system_expande -->|"related to"| enteric_nervous_system_expande
style enteric_nervous_system_expande fill:#81c784,stroke:#333,color:#000
enteric_nervous_system_expande["called"]
enteric_nervous_system_expande -->|"related to"| enteric_nervous_system_expande
style enteric_nervous_system_expande fill:#81c784,stroke:#333,color:#000
style enteric_nervous_system_expande fill:#4fc3f7,stroke:#333,color:#000
The enteric nervous system (ENS) is often called the "second brain" due to its complex network of neurons embedded in the gastrointestinal tract wall. With approximately 100 million neurons—roughly the same number as in the spinal cord—the ENS controls gut motility, secretion, blood flow, and immune functions autonomously, though it communicates extensively with the central nervous system (CNS) via the vagus nerve and sympathetic pathways. [@furnish2019]
...Enteric Nervous System
Introduction
Mermaid diagram (expand to render)
The enteric nervous system (ENS) is often called the "second brain" due to its complex network of neurons embedded in the gastrointestinal tract wall. With approximately 100 million neurons—roughly the same number as in the spinal cord—the ENS controls gut motility, secretion, blood flow, and immune functions autonomously, though it communicates extensively with the central nervous system (CNS) via the vagus nerve and sympathetic pathways. [@furnish2019]
In recent years, the ENS has emerged as a critical player in neurodegenerative diseases, particularly Parkinson's disease (PD), where the gut-brain axis hypothesis proposes that pathology originates in the gastrointestinal tract and propagates retrogradely to the brain via the vagus nerve. This theory has profound implications for understanding disease initiation, early detection, and therapeutic intervention. [@braak2003]
Anatomy and Cellular Organization
Structural Organization
The ENS is organized into two major ganglionated plexuses:
- Myenteric plexus (Auerbach's plexus): Located between the longitudinal and circular muscle layers; primarily controls gut motility and peristalsis
- Submucosal plexus (Meissner's plexus): Located in the submucosa; regulates intestinal secretion, absorption, and blood flow
These plexuses contain various neuronal subtypes, including sensory neurons, interneurons, and motor neurons, forming complete reflex circuits capable of autonomous function. [@furnish2019]
Enteric Glia
Enteric glial cells (EGCs) are essential for ENS function, analogous to astrocytes in the CNS:
- Morphology: star-shaped cells ensheathing neuronal soma and processes
- Markers: GFAP, S100B, Sox10
- Functions:
- Metabolic support for neurons (lactate shuttling)
- Maintenance of the intestinal epithelial barrier
- Modulation of immune responses
- Regulation of neurotransmission
- Support of neuronal survival during stress
EGCs respond to pathogens and inflammation by producing pro-inflammatory cytokines, and their dysfunction contributes to ENS pathology in PD.
PMID: 31026437(https://pubmed.ncbi.nlm.nih.gov/31026437/)
Interstitial Cells of Cajal (ICCs)
ICCs serve as pacemakers in the gastrointestinal tract:
- Location: Within muscle layers, particularly the myenteric plexus region
- Function: Generate slow-wave potentials that coordinate rhythmic gut contractions
- Markers: c-KIT (CD117), ANO1
- Pathology in PD: ICC loss correlates with gastroparesis in PD patients
Enteroendocrine Cells
Enteroendocrine cells (EECs) represent the largest endocrine organ in the body:
- Types: CCK cells, G cells, EC cells (serotonin), L cells (GLP-1, PYY)
- Function: Sense nutrients, release hormones regulating satiety, glucose homeostasis
- Connection to neurodegeneration: EECs express alpha-synuclein and may serve as reservoirs for pathology spread
Molecular Markers and Neurochemistry
Neurotransmitter Systems
The ENS employs multiple neurotransmitter systems:
| Neurotransmitter | Function | Neuron Population |
|-----------------|----------|-------------------|
| Acetylcholine | Excitatory motor | Cholinergic neurons |
| Nitric oxide | Inhibitory motor | Nitrergic neurons |
| VIP | Secretion, relaxation | VIPergic neurons |
| Substance P | Excitatory sensory | Tachykinergic neurons |
| Serotonin | Motility modulation | Serotonergic neurons |
| CGRP | Sensory signaling | CGRP neurons |
| ATP | Fast excitatory | Purinergic neurons |
Neuropeptides
Beyond classical neurotransmitters, the ENS expresses numerous neuropeptides:
- Galanin: Co-released with norepinephrine; modulates enteric motility
- Neuropeptide Y (NPY): Inhibits secretion and motility
- Somatostatin: Inhibits release of other peptides
- Bombesin: Regulates satiety and gastric acid secretion
Role in Parkinson's Disease
The Braak Hypothesis
In 2003, Braak and colleagues proposed that idiopathic Parkinson's disease begins with an unknown pathogen entering the body through the nasal cavity or gastrointestinal tract, triggering alpha-synuclein pathology in vulnerable neuronal populations. [@braak2003] According to this model:
Stage 1-2: Pathology confined to the enteric nervous system and dorsal motor nucleus of the vagus
Stage 3-4: Pathology spreads to the substantia nigra and other brainstem nuclei
Stage 5-6: Neocortical involvementThis staged progression implies that the ENS may harbor the initiating pathological events years before motor symptoms appear. [@chandra2019]
Alpha-Synuclein in the ENS
Phosphorylated alpha-synuclein (pSer129):
- Pathological hallmark of PD in the ENS
- Detected in 50-80% of early PD patients via gastrointestinal biopsy
- Found in individuals with idiopathic REM sleep behavior disorder (iRBD), a PD prodrome
Distribution pattern:
- Proximal GI tract (esophagus, stomach) affected before distal (colon)
- Myenteric plexus more vulnerable than submucosal plexus
- Specific neuronal subtypes show differential vulnerability
Evidence from Studies
Gastrointestinal alpha-synuclein in premotor PD:
- phosphorylated alpha-synuclein (pSer129) deposits detected in ENS neurons of individuals with idiopathic REM sleep behavior disorder (iRBD), a PD prodrome
- Studies show 50-80% of early PD patients have detectable ENS pathology at biopsy
- The pattern of involvement follows a proximal-to-distal gradient, with the esophagus and stomach affected before the colon
Clinical correlates:
- Constipation precedes motor PD by 10-20 years in most patients
- Other GI symptoms including dysphagia, nausea, and gastroparesis are common in prodromal stages
- PMID: 20887898(https://pubmed.ncbi.nlm.nih.gov/20887898/)
Mechanisms of Propagation
Several hypotheses explain how alpha-synuclein pathology might spread from ENS to CNS: [@borghammer2021]
Retrograde vagal transport: alpha-synuclein fibrils internalized by enteric neurons undergo retrograde axonal transport via the vagus nerve to the dorsal motor nucleus
Trans-synaptic spread: Prion-like templated aggregation propagates across synapses from ENS to CNS neurons
Hematogenous spread: Pathological proteins enter circulation and cross the blood-brain barrier
Immune-mediated transport: Activated immune cells carry alpha-synuclein from gut to brainSupporting Evidence
Epidemiological studies:
- PMID: 19145172(https://pubmed.ncbi.nlm.nih.gov/19145172/)
- PMID: 21810660(https://pubmed.ncbi.nlm.nih.gov/21810660/)
- Vagotomy associated with reduced PD risk in some cohort studies
Neuroimaging:
- PMID: 25925842(https://pubmed.ncbi.nlm.nih.gov/25925842/)
- Altered vagal tone in early PD measured by heart rate variability
Animal models:
- PMID: 31194225(https://pubmed.ncbi.nlm.nih.gov/31194225/)
- Rodent studies demonstrate vagal propagation of alpha-synuclein
Gut Microbiome and Neuroinflammation
Dysbiosis in Parkinson's Disease
Multiple studies have documented altered gut microbiota in PD patients: [@sampson2016]
- Reduced microbial diversity
- Increased Prevotellaceae, Enterobacteriaceae
- Decreased Bacteroidetes, Lachnospiraceae
- Elevated intestinal permeability ("leaky gut")
Gut bacteria produce metabolites that influence CNS function:
- Short-chain fatty acids (SCFAs): Butyrate, propionate; reduced in PD; modulate microglial activation
- LPS from gram-negative bacteria: Triggers neuroinflammation when translocated across leaky gut
- Trimethylamine N-oxide (TMAO): Elevated in PD; associated with mitochondrial dysfunction
Evidence from Animal Models
Germ-free mice colonized with PD patient fecal microbiota show: [@caputi2022]
- Enhanced motor deficits
- Increased alpha-synuclein aggregation in brain
- Reduced microglial ramification
- Elevated intestinal inflammation
These findings suggest that gut microbiota can directly modulate CNS pathology. [@johnson2020]
Other Neurodegenerative Diseases
Alzheimer's Disease
While less studied than in PD, ENS involvement in AD includes:
- PMID: 32581342(https://pubmed.ncbi.nlm.nih.gov/32581342/)
- Amyloid-beta deposits detected in ENS neurons
- Altered gut motility in AD patients
- Gut microbiome changes correlate with cognitive decline
Multiple System Atrophy (MSA)
MSA shows distinct gastrointestinal involvement:
- PMID: 31965087(https://pubmed.ncbi.nlm.nih.gov/31965087/)
- Severe autonomic dysfunction including gastrointestinal failure
- Different pattern of ENS pathology compared to PD
Amyotrophic Lateral SALS (ALS)
Gastrointestinal dysfunction in ALS:
- PMID: 30896515(https://pubmed.ncbi.nlm.nih.gov/30896515/)
- Malnutrition and weight loss major concerns
- Altered gut microbiome in ALS mouse models
- Potential therapeutic implications
Clinical Implications
Diagnostic Potential
Gastrointestinal biopsies:
- Rectal or colonic biopsies can detect phosphorylated alpha-synuclein
- Sensitivity for early PD: ~70-80%
- May enable premotor diagnosis in at-risk individuals
Microbiome-based biomarkers:
- Microbial signatures associated with PD diagnosis
- Potential for non-invasive screening
Breath and fecal markers:
- Volatile organic compounds (VOCs) as biomarkers
- Fecal calprotectin for gut inflammation
Therapeutic Approaches
Targeting the gut:
- Probiotics: Lactic acid bacteria trials show improvement in motor symptoms and constipation
- Fecal microbiota transplantation (FMT): Investigational; case reports suggest benefit
- Dietary interventions: Mediterranean diet, prebiotic fiber supplementation
Preventing propagation:
- Vagotomy: Historical studies suggest reduced PD risk after truncal vagotomy
- Blood-brain barrier modulation: Targeting transport mechanisms
Current pharmacological approaches:
ENS in Aging and Cellular Senescence
The ENS undergoes significant changes with aging:
- PMID: 28730439(https://pubmed.ncbi.nlm.nih.gov/28730439/)
- Declining neuronal numbers
- Glial reactivity
- Reduced mitochondrial function
- Altered neurotransmitter production
Cellular Senescence
Senescent enteric neurons exhibit:
- PMID: 30224658(https://pubmed.ncbi.nlm.nih.gov/30224658/)
- SA-β-gal positivity
- SASP (Senescence-Associated Secretory Phenotype) production
- Pro-inflammatory cytokine release
- Impaired mitochondrial biogenesis
Enteric Neuronal Vulnerability in Neurodegeneration
Selective Vulnerability
Not all ENS neurons are equally vulnerable to pathological insults:
- Most vulnerable: cholinergic motor neurons, nitrergic inhibitory neurons
- More resistant: serotonergic neurons, CGRP sensory neurons
- Molecular basis: Differential expression of proteins involved in protein homeostasis, mitochondrial function, and oxidative stress response
Mechanisms of Vulnerability
Protein aggregation burden: Enteric neurons accumulate alpha-synuclein with aging
Mitochondrial dysfunction: High energy demands make ENS neurons susceptible
Oxidative stress: GI tract exposure to dietary oxidants
Immune privilege: ENS immune cells differ from CNS, potentially altering responsesFuture Directions and Research Gaps
Unresolved Questions
What triggers initial alpha-synuclein aggregation in the ENS?
How does the gut microbiome influence alpha-synuclein pathology?
Can ENS biopsy serve as a definitive diagnostic tool?
What is the natural history of ENS pathology in at-risk individuals?Emerging Research Areas
- Single-cell transcriptomics of enteric neurons in PD
- Organoid models of the ENS
- Targeting gut inflammation as disease-modifying therapy
- Development of gut-restricted neuroprotective agents
Summary
The enteric nervous system, once viewed primarily as an autonomous regulator of gastrointestinal function, now occupies a central position in neurodegenerative disease research. The gut-brain axis provides a compelling framework for understanding how alpha-synuclein pathology might initiate in the ENS and propagate to the CNS, potentially decades before clinical diagnosis. This paradigm shift opens new avenues for early detection, disease-modifying therapies, and ultimately, prevention of Parkinson's disease and related alpha-synucleinopathies.
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein Propagation](/mechanisms/alpha-synuclein-propagation)
- [Gut-Brain Axis in Neurodegeneration](/mechanisms/gut-brain-axis)
- [Vagus Nerve](/cell-types/vagus-nerve-neurons)
References
[Furness JB. The enteric nervous system: A review. J Neurogastroenterol Motil. 2019](https://doi.org/10.1111/jghm.2019.25.1.5)
[Braak et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion. J Neural Transm. 2003](https://doi.org/10.1007/s00702-003-0008-7)
[Chandra et al. Neuronal alpha-synuclein disease in the gastrointestinal tract prior to Parkinson's disease. J Parkinsons Dis. 2019](https://doi.org/10.3233/JPD-191709)
[Borghammer & Van Den Berge. Alpha-synucleinopathies: A bottom-up model of the gut-to-brain spread. J Intern Med. 2021](https://doi.org/10.1111/joim.13206)
[Derkinderen et al. Gut-to-brain propagation of alpha-synucleinopathy. J Parkinsons Dis. 2020](https://doi.org/10.3233/JPD-202177)
[Matheoud et al. Intestinal infection triggers Parkinson's disease in mice. Nature. 2019](https://doi.org/10.1038/s41586-019-1405-y)
[Sampson et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016](https://doi.org/10.1016/j.cell.2016.11.018)
[Johnson et al. The gut-brain axis in Parkinson's disease. Gastroenterology. 2020](https://doi.org/10.1053/j.gastro.2019.12.028)
[Caputi et al. The role of the gut microbiome in neurodegeneration. J Neurochem. 2022](https://doi.org/10.1111/jnc.15632)